Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DRM02 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| DRM02 | EXPERIMENTAL | DRM02 Topical Gel, 0.25% |
| Vehicle | PLACEBO_COMPARATOR | DRM02 Topical Gel, Vehicle |
| Name | Type | Description |
|---|---|---|
| DRM02 | DRUG | - |
| Vehicle | OTHER | - |
Inclusion Criteria: * Male or female 18 to 70 years of age. * Plaque-type psoriasis with two lesions of similar size and have an identical score of at least 6 but no more than 8 on the sum of the individual components of the Severity of Psoriasis Area Severity Index (PASI) at the Target Lesion scal...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
DRM02 is an investigational small molecule drug being developed by Eli Lilly and Company for dermatological conditions. It has been studied in Phase 2 clinical trials for plaque psoriasis and rosacea. DRM02 is not approved and remains in clinical development.
DRM02 has been studied for the treatment of plaque psoriasis and rosacea, two inflammatory skin conditions. Both Phase 2 trials enrolled adults aged 18 years and older. The drug is investigational and has not been approved for any indication.
DRM02 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program evaluating DRM02 in dermatology indications.
DRM02 is in Phase 2 development. Two Phase 2 trials have been completed: one in rosacea and one in plaque psoriasis. The drug is investigational and has not received FDA approval for any indication.
DRM02 has been evaluated in two completed Phase 2 trials. NCT01993446 studied DRM02 in 30 subjects with rosacea, and NCT01993433 studied it in 23 subjects with plaque psoriasis. Both were randomized, double-blind, placebo-controlled studies conducted in Canada.